Ask AI
Back Back
Risk Factors for Progression in PBC

CE / CME

Identifying Risk Factors for Disease Progression and Poor Response in PBC: Implications for First-line Therapy

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: maximum of 0.75 AMA PRA Category 1 Credit™

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: March 30, 2026

Expiration: March 29, 2027

Sonal Kumar
Sonal Kumar, MD, MPH
CME/CE Information

Activity

Progress
1 2 3
Course Completed

Why Early Identification of High-Risk PBC Matters

When a patient is diagnosed with PBC, American Association for the Study of Liver Diseases (AASLD) guidelines recommend determining the degree of fibrosis, initiating first-line therapy with UDCA, and then assessing biochemical response after 1 year of treatment.1

However, PBC has a variable rate of progression. As a result, there is no one-size-fits-all approach for managing PBC. Although the general framework of diagnosis and treatment remains similar, it is important to identify individualized factors that may place a patient at higher risk.2,3

Recognizing high-risk features early allows us to intervene sooner in people who are most likely to experience disease progression. Early identification and intervention may help alter the disease course and ultimately reduce the risk of poor liver-related outcomes.2,3

Download

Recent Changes in PBC Treatment Paradigm

Historically, the treatment paradigm for PBC followed a fairly rigid stepwise approach. After diagnosis, biochemical response was assessed in everyone at 12 months. Now, this paradigm is evolving so that higher-risk patients are assessed at 6 months instead of 12.4

Download

UDCA Remains Standard First-line Therapy

UDCA remains the standard first-line therapy for PBC.1 UDCA is dosed based on body weight, with a recommended total daily dose of 13-15 mg/kg/day. The medication is often divided into twice-daily dosing, although the timing of doses may be less important than previously thought.5

Although UDCA is generally well tolerated, a small proportion of people are unable to tolerate this therapy. In addition, approximately 40% of people are considered inadequate responders to UDCA and may require additional therapy.1,5

Download

Individualized Monitoring for People With High-Risk PBC

All people with PBC require an individualized monitoring strategy. In those with high-risk features or multiple risk factors for disease progression, it may be appropriate to assess treatment response earlier and monitor more closely.1

For example, in people with advanced fibrosis, I assess response to first-line therapy at 6 months rather than waiting until the traditional 12-month time point. The goal is to identify inadequate response earlier and intervene before further disease progression occurs.

Before determining that a person is not responding to therapy, it is important to confirm adherence to UDCA.1 Other factors that may influence liver test abnormalities should also be considered.6,7

If treatment goals are not achieved, particularly in people at higher risk, second-line therapy should be considered.1,8,9

Download

Consider Assessing Response at 6 Mo in Higher-Risk People

With the recent emphasis on earlier treatment assessment, it is important to understand why the PBC treatment paradigm is shifting this way.

A retrospective study of people with PBC treated with UDCA evaluated treatment response in terms of ALP levels at 6 and 12 months post treatment initiation. In this analysis, approximately two thirds of patients who were classified as nonresponders at 12 months could have been identified as early as 6 months based on ALP levels.10

These findings suggest that earlier evaluation of treatment response, particularly in patients with higher-risk disease, may allow healthcare professionals to identify inadequate responders sooner and consider adjustments in management.10

Download
BACK | NEXT